Cargando…
In Vitro Drug Repurposing: Focus on Vasodilators
Drug repurposing aims to identify new therapeutic uses for drugs that have already been approved for other conditions. This approach can save time and resources compared to traditional drug development, as the safety and efficacy of the repurposed drug have already been established. In the context o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954697/ https://www.ncbi.nlm.nih.gov/pubmed/36831338 http://dx.doi.org/10.3390/cells12040671 |
_version_ | 1784894180692066304 |
---|---|
author | Ribeiro, Eduarda Costa, Bárbara Vasques-Nóvoa, Francisco Vale, Nuno |
author_facet | Ribeiro, Eduarda Costa, Bárbara Vasques-Nóvoa, Francisco Vale, Nuno |
author_sort | Ribeiro, Eduarda |
collection | PubMed |
description | Drug repurposing aims to identify new therapeutic uses for drugs that have already been approved for other conditions. This approach can save time and resources compared to traditional drug development, as the safety and efficacy of the repurposed drug have already been established. In the context of cancer, drug repurposing can lead to the discovery of new treatments that can target specific cancer cell lines and improve patient outcomes. Vasodilators are a class of drugs that have been shown to have the potential to influence various types of cancer. These medications work by relaxing the smooth muscle of blood vessels, increasing blood flow to tumors, and improving the delivery of chemotherapy drugs. Additionally, vasodilators have been found to have antiproliferative and proapoptotic effects on cancer cells, making them a promising target for drug repurposing. Research on vasodilators for cancer treatment has already shown promising results in preclinical and clinical studies. However, additionally research is needed to fully understand the mechanisms of action of vasodilators in cancer and determine the optimal dosing and combination therapy for patients. In this review, we aim to explore the molecular mechanisms of action of vasodilators in cancer cell lines and the current state of research on their repurposing as a treatment option. With the goal of minimizing the effort and resources required for traditional drug development, we hope to shed light on the potential of vasodilators as a viable therapeutic strategy for cancer patients. |
format | Online Article Text |
id | pubmed-9954697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99546972023-02-25 In Vitro Drug Repurposing: Focus on Vasodilators Ribeiro, Eduarda Costa, Bárbara Vasques-Nóvoa, Francisco Vale, Nuno Cells Review Drug repurposing aims to identify new therapeutic uses for drugs that have already been approved for other conditions. This approach can save time and resources compared to traditional drug development, as the safety and efficacy of the repurposed drug have already been established. In the context of cancer, drug repurposing can lead to the discovery of new treatments that can target specific cancer cell lines and improve patient outcomes. Vasodilators are a class of drugs that have been shown to have the potential to influence various types of cancer. These medications work by relaxing the smooth muscle of blood vessels, increasing blood flow to tumors, and improving the delivery of chemotherapy drugs. Additionally, vasodilators have been found to have antiproliferative and proapoptotic effects on cancer cells, making them a promising target for drug repurposing. Research on vasodilators for cancer treatment has already shown promising results in preclinical and clinical studies. However, additionally research is needed to fully understand the mechanisms of action of vasodilators in cancer and determine the optimal dosing and combination therapy for patients. In this review, we aim to explore the molecular mechanisms of action of vasodilators in cancer cell lines and the current state of research on their repurposing as a treatment option. With the goal of minimizing the effort and resources required for traditional drug development, we hope to shed light on the potential of vasodilators as a viable therapeutic strategy for cancer patients. MDPI 2023-02-20 /pmc/articles/PMC9954697/ /pubmed/36831338 http://dx.doi.org/10.3390/cells12040671 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ribeiro, Eduarda Costa, Bárbara Vasques-Nóvoa, Francisco Vale, Nuno In Vitro Drug Repurposing: Focus on Vasodilators |
title | In Vitro Drug Repurposing: Focus on Vasodilators |
title_full | In Vitro Drug Repurposing: Focus on Vasodilators |
title_fullStr | In Vitro Drug Repurposing: Focus on Vasodilators |
title_full_unstemmed | In Vitro Drug Repurposing: Focus on Vasodilators |
title_short | In Vitro Drug Repurposing: Focus on Vasodilators |
title_sort | in vitro drug repurposing: focus on vasodilators |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954697/ https://www.ncbi.nlm.nih.gov/pubmed/36831338 http://dx.doi.org/10.3390/cells12040671 |
work_keys_str_mv | AT ribeiroeduarda invitrodrugrepurposingfocusonvasodilators AT costabarbara invitrodrugrepurposingfocusonvasodilators AT vasquesnovoafrancisco invitrodrugrepurposingfocusonvasodilators AT valenuno invitrodrugrepurposingfocusonvasodilators |